Persistence of immunity to hepatitis B vaccine as infants, 17 years earlier
Authors
Abstract:
Background: In Iran scince 1992, hepatitis B vaccination was a part of the national vaccination program. Hepatitis B vaccination is effective in the epidemiology of hepatitis B. The aim ofthis study was to evaluate the long – term persistence of immunity. Methods: This cross-sectional analytical study was conducted on children and adolescents aged between 6-18 years in Birjand, who received a three – dose hepatitis B vaccination in accordance with the national immunization program. No students were infected with hepatitis B. Antibody titer higher than10 IU/L was considered positive. Results: A total of 530 patients (307 boys and 223 girls) were recruited for the study of which 44% had positive antibody titer (≥10 IU / L). The geometric concentration mean (GMCs) of antibody in subjects was 64.9±34.2, HBS antibody titer was positive in 40.4% of the boys and 59.6% of the girls. A significant difference in antibody titers was observed in terms of gender and according to the time elapsed since the last vaccination. Antibody titer in children older than 13 years had passed since their last vaccination and was significantly less than those children younger than thirteen years old had passed since their vaccination logistic regression analysis showed that the only predictive factor of anti-HBS low titer (<10 IU/L) is elapsed time of vaccination. Conclusions: Based on results of this study hepatitis B vaccine has created a good level of protection in 44% of the adolescents after 17 years
similar resources
The factors influencing the immune response to hepatitis B vaccine and persistence of the protection.
Hepatitis B virus (HBV) infection and its sequelae which include cirrhosis and hepatocellular carcinoma is a major public health problem throught the world.The WHO strategy for effective control of HBV infection is vaccination with the surface antigen of virus(HBsAg).The results obtained from a large number of studies demonstrated that the vaccine induces a protective antibody resonse (anti-HB...
full textHepatitis B vaccine immunogenicity in Kerman 12 months infants
Introduction: Infection with HBV is the most common chronic viral infection and mortality in children. Prevention of this infection with vaccination is vital. This study was done to compare the antibody level in post hepatitis B vaccination in children with 12 months age. Materials and Methods:This descriptive study was carreid out on healthy 120 children ...
full textImmunity to Hepatitis B Vaccine in Thalassaemic Patients based on the Time Passed from Vaccination
Background & Aims: Hepatitis B virus is one of the causes of acute and chronic hepatitis. Due to multiple hospitalization and blood transfusion, thalassaemic patients are at higher risk of this infection. Duration of the immunity after vaccination in this high-risk group and the need for booster vaccination is uncertain. The aim of this study was to find antibody titration and immunity to Hepat...
full textSTUDY ON THE EF FICACY OF RECOMBINANT HEPATITIS B VACCINE IN IRANIAN INFANTS
In order to determine the efficacy of recombinant hepatitis B vaccine in Iranian infants, we analyzed the efficacy of a recombinant hepatitis B vaccine in 115 infants aged 12-24 months born to HBsAg negative mothers who received three doses of HBV Antibody to hepatitis B surface antigen (anti-HBs) was checked after the third dose of the vaccine, 94.8% of the infants had developed protective...
full textEffect of Sucrose 30% on Hepatitis B Vaccine Injection Pain Relief in Full Term Infants
Background and Objectives: Several studies have shown that sucrose intake results in pain relief during painful procedures among neonates. The effect of sucrose intake on intramuscular injection pain have less been studied. The aim of this study was to assess the effect of oral sucrose 30% on pain relief of Hepatitis B vaccine injection in full-term infants. Materials and Methods: In this tripl...
full textLong-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers.
Neonates of hepatitis B surface antigen (HBsAg) positive and hepatitis B encoded antigen (HBeAg) positive mothers received 10 micrograms of recombinant hepatitis B vaccine at months 0, 1, 6, or 0, 1, 2, 12, with or without immunoglobulin at birth, and were followed up to the age of 8 years for HBsAg, anti-HBc, and anti-HBs. Some were boosted at month 60. The overall vaccine protection at month ...
full textMy Resources
Journal title
volume 9 issue None
pages 184- 188
publication date 2018-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023